Halozyme Appoints Darren Snellgrove as CFO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy HALO?
Halozyme Therapeutics (HALO) announced the appointment of Darren Snellgrove as CFO, effective June 8. Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and CEO. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson (JNJ). In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 64.120
Low
56.00
Averages
78.50
High
90.00
Current: 64.120
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: Halozyme Therapeutics (HALO) is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of $1.52, reflecting a 36.9% year-over-year growth, indicating sustained improvement in profitability.
- Revenue Expectations: Analysts forecast that Halozyme's Q1 revenue will reach $359.05 million, representing a 35.5% year-over-year increase, which underscores the strong market demand and growth potential in the drug delivery technology sector.
- Performance Beat Record: Over the past two years, HALO has exceeded EPS and revenue estimates 88% of the time, a track record that not only boosts investor confidence but also lays a solid foundation for future growth.
- Estimate Revision Dynamics: Despite no upward revisions in EPS and revenue estimates over the last three months, with four downward adjustments each, this may reflect a cautious market sentiment regarding short-term performance, although the company remains competitively strong.
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
Global Collaboration Announcement: Haloyzime has announced a global collaboration and licensing agreement with GSK.
Focus on Oncology: The partnership aims to develop subcutaneous formulations targeting multiple promising oncology therapies.
See More
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
Halozyme Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: Halozyme Therapeutics (HALO) is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of $1.52, reflecting a 36.9% year-over-year growth, indicating sustained improvement in profitability.
- Revenue Expectations: Analysts forecast that Halozyme's Q1 revenue will reach $359.05 million, representing a 35.5% year-over-year increase, which underscores the strong market demand and growth potential in the drug delivery technology sector.
- Performance Beat Record: Over the past two years, HALO has exceeded EPS and revenue estimates 88% of the time, a track record that not only boosts investor confidence but also lays a solid foundation for future growth.
- Estimate Revision Dynamics: Despite no upward revisions in EPS and revenue estimates over the last three months, with four downward adjustments each, this may reflect a cautious market sentiment regarding short-term performance, although the company remains competitively strong.
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
Global Collaboration Announcement: Haloyzime has announced a global collaboration and licensing agreement with GSK.
Focus on Oncology: The partnership aims to develop subcutaneous formulations targeting multiple promising oncology therapies.
See More
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
